Company News: Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC
— First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer (ISA101-CervISA) will be presented at the inaugural ASCO-SITC congress on immuno-oncology (February 23-25, 2017, Orlando, FL, USA).
An oral and a poster presentation will be held by Prof. Cornelis Melief and Marij Welters, PhD, on Thursday, February 23, 2017:
“Poster Session A”: 11:30AM-1:00PM and 5:30PM-6:30PM (Cornelis Melief)
“Oral Abstract session A”: 1:00PM-2:15PM (Marij Welters)
The data will be based on the abstract titled “Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer” (abstract no. 140). The company intends to publish the data in a peer-reviewed journal later this year.